Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

diphtheria toxoid/tetanus toxoid/acellular pertussis adsorbed, recombinant hepatitis B/inactivated poliovirus vaccine combined

A vaccine consisting of detoxified tetanus toxoid, detoxified diphtheria toxoid, acellular pertussis antigens, inactivated poliovirus (IPV) types 1,2 and 3 and hepatitis B (HBV) surface antigen, with active immunizing activities against diphtheria, tetanus, pertussis, hepatitis B, and poliomyelitis. The acellular pertussis components in this vaccine, produced by Bordetella pertussis, are detoxified pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (PRN). Upon intramuscular injection, this vaccine activates the immune system to develop antibodies against tetanus toxin, diphtheria toxin, B. pertussis antigens, polioviruses and HBV. The diphtheria and tetanus toxoids and pertussis antigens (inactivated PT, FHA, and pertactin) are adsorbed onto aluminum hydroxide; the hepatitis B antigen is adsorbed onto aluminum phosphate.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
US brand name:PEDIARIX
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search